目的：为临床合理用药提供参考。方法：对长江流域273家样本医院2014年药品销售金额、用药频度（DDDs）、日均费用（DDC）及主要生产厂商等数据进行统计分析。结果：药品销售金额增长呈逐步放缓的节奏；抗感染药物、心血管系统用药以及神经系统用药占据前3位。连续4个季度销售金额排名前3位的药品分别是单唾液四己糖神经节苷脂、胸腺肽和兰索拉唑；排名前15位的药品中近一半是辅助药物；中成药日益升温并逐步出现在排行榜上。销售厂商以国产厂商居多，主要集中在四川、重庆和江苏等地。结论：样本医院用药结构与我国疾病谱基本相符，但一些辅助药物的使用与国际指南存在偏差，临床用药合理性有待提高。%OBJECTIVE:To provide reference for clinical rational drug use. METHODS:The drug sales amount,DDDs, DDC and major pharmaceutical enterprises in 273 sample hospitals of Yangtze River basin in 2014 were statistically analyzed. RE-SULTS:The growth of consumption sum slowed down gradually. The anti-infective drugs,cardiovascular drugs and nervous sys-tem drugs occupied the medical mainstream market. Top 3 drugs in the list of consumption sum in consecutive 4 quarters were monosialotetrahexosylganglioside,thymic peptide and lansoprazole. Nearly half of top 15 drugs were auxiliary drugs;Chinese pat-ent medicines grew increasingly and appeared in the list. The sales enterprises were mainly domestic enterprises,which concentrat-ed in Sichuan,Chongqing,Jiangsu province,and other places. CONCLUSIONS:The structure of drug use in sample hospitals is basically consistent with the spectrum of disease in China. However,there is deviation between auxiliary drug use and international guide,and the rationality of clinical drug use needs to be improved.
展开▼
